瑞舒伐他汀治疗老年2型糖尿病合并冠心病患者的临床疗效

目的观察老年2型糖尿病合并冠心病患者接受瑞舒伐他汀治疗的疗效。方法 86例2型糖尿病合并冠心病患者依据治疗方法的不同分为观察组45例(瑞舒伐他汀+常规治疗)及对照组41例(常规治疗)。治疗12周后观察疗效。结果治疗后,观察组患者TC及LDL-C均显著降低,并显著低于对照组(P0.05);HDL-C水平显著升高,且显著高于对照组(P0.05)。治疗后,观察组患者外周血IL-6及CRP水平均显著降低,且显著低于对照组(P0.05)。治疗后,观察组患者NO及LVEF均显著升高(P0.05),且显著高于对照组(P0.05);观察组ET水平显著降低(P0.05),且显著低于对照组(P0.05)。观察组患者累积主要不良心脏事件发生率显著低于对照组患者(P=0.036)。结论瑞舒伐他汀可有效改善老年2型糖尿病合并冠心病患者的心血管功能。

Clinical efficacy of rosuvastatin in treatment of elderly patients with type 2 diabetes mellitus and coronary heart disease

Objective To observe the curative effect of rosuvastatin on treatment of elderly patients with type 2 diabetes mellitus complicated with coronary heart disease.Methods A total of 86 patients with type 2 diabetes mellitus complicated with coronary heart disease were divided into observation group (n =45,rosuvastatin plus conventional therapy) and control group (n =41,conventional treatment).After 12 weeks of treatment,the therapeutic effect was observed.Results After treatment,in the observation group,the LDL-C and TC significantly reduced,and were significantly lower than the control group (P ＜ 0.05).Level of HDL-C increased significantly in the observation group,and was significantly higher than the control group (P ＜ 0.05).After treatment,the levels of IL-6 and CRP in the peripheral blood of the observation group were significantly lower than those of the control group (P ＜ 0.05).After treatment,in the observation group,the NO and LVEF increased significantly,and were significantly higher than the control group (P ＜ 0.05).The level of ET in the observation group decreased significantly,and was significantly lower than the control group (P ＜ 0.05).In the observation group,the cumulative major adverse cardiac event rate was significantly lower than that of the control group (P =0.036).Conclusion Rosuvastatin can effectively improve the cardiovascular function in elderly patients with type 2 diabetes mellitus and coronary heart disease.